



Press Release
For immediate release

Advanced BioDesign Strengthens Early Access Program Outcomes, Confirms Steady Progress of ODYSSEY Clinical Trial, and Announces Upcoming Scientific Presentations

Lyon, France – 23rd of March 2026 — Advanced BioDesign, a biotechnology company developing first-in-class ALDH1 inhibitors for treatment-resistant cancers, today released an update on the progress of its Early Access Program (EAP), the advancement of its ODYSSEY first-in-human clinical trial, and the participation of its clinical investigators in upcoming scientific conferences.

Strong performance of the Early Access Program

Open since early 2025, the Early Access Program has enabled physicians to treat five patients who were not eligible to participate in the ODYSSEY clinical study. All patients continued treatment beyond the three initial cycles, resulting in a 100% continuation rate over the past year.

These results highlight the feasibility of using ABD-3001 in real-world settings and the sustained clinical benefit observed by treating physicians.

ODYSSEY clinical trial progressing on schedule

The company is pleased to report that its ODYSSEY Phase I first-in-human clinical trial evaluating ABD-3001 in patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) is progressing according to the timeline. The next major milestone, the Safety Review Committee (SRC), is scheduled for late April, keeping the program aligned with its planned development trajectory.

Upcoming scientific presentations by ODYSSEY investigators in Société Française d'Hématologie congress which will be held in Paris from 25th to 27th of March.

Several ODYSSEY clinical investigators will present new scientific results at upcoming international conferences:

Oral Presentation – Pr. Régis Costello: ***“ALDH1 as a mediator of adaptive resistance to anthracyclines in acute myeloid leukemia.”*** This presentation will highlight the mechanistic role of ALDH1 in chemotherapy resistance and the rationale for targeting this pathway with ABD-3001.

Poster Presentation – ODYSSEY Clinical Trial Update: ***“ODYSSEY: Phase I first-in-human study of the aldehyde dehydrogenase (ALDH) inhibitor ABD-3001 in patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).”*** The poster will provide new data and insights on safety, tolerability, and early signs of clinical activity.

Commitment to innovation for patients with high unmet needs

Advanced BioDesign continues to accelerate the development of ABD-3001, a first-in-class ALDH1 inhibitor designed to overcome cancer cell resistance mechanisms. The company remains committed to working closely with clinicians and regulatory bodies to bring new therapeutic options to patients who lack alternatives.

About ABD-3001

ABD-3001 is the pharmaceutical formulation of DIMATE, a first-in-class “suicide” inhibitor of class I aldehyde dehydrogenases (ALDH1). This innovative compound was developed to target a critical survival pathway in cancer cells. Its mechanism of action involves inhibition of ALDH enzymes, which are frequently exploited by tumor cells to mitigate oxidative stress. ALDH inhibition induces intracellular redox imbalance, ultimately leading to cancer cell death while largely sparing normal cells. This therapeutic strategy is designed to overcome resistance mechanisms associated with standard chemotherapy and currently available targeted therapies.

DIMATE is currently being evaluated in a Phase 1 clinical trial (ODYSSEY) and may represent a novel therapeutic option for patients with limited or no remaining treatment alternatives.

About the ODYSSEY clinical trial

ODYSSEY is a Phase I/II clinical trial for the treatment of relapse and refractory acute myeloid leukemia (AML). It is a multicenter study, with centers in Paris, Lyon and Marseille, designed to assess the safety and tolerability of the drug candidate ABD-3001.

Following an adaptive design, the study integrates an ascending single-dose first part, on six patient cohorts, followed by a second part, during which three patient cohorts will receive full four-week treatment cycles, enabling initial efficacy results to be obtained.

Fully funded by Advanced BioDesign, the ODYSSEY clinical trial is coordinated by Professor Régis COSTELLO (Hôpital de la Conception, Marseille), in collaboration with Professor Lina BENAÏBA (Hôpital Saint-Louis, Paris), and Doctor Maël HEIBLIG (Hôpital Lyon Sud, Lyon).

About Acute Myeloid Leukemia

Acute myeloid leukemia (AML) represents an approximately USD 1.5 billion global market, characterized by limited therapeutic innovation in both frontline and salvage settings. Despite the introduction of targeted therapies such as azacitidine–venetoclax, anthracycline- and cytarabine-based chemotherapy remains the backbone of treatment, and primary or acquired resistance continues to drive poor clinical outcomes. By targeting a critical resistance mechanism, Advanced BioDesign’s ALDH1-directed therapeutic strategy has the potential to meaningfully reshape the treatment paradigm, enable rational combination regimens, and capture substantial market share in both relapsed/refractory and high-risk AML populations.

About Advanced BioDesign

Advanced BioDesign is a clinicalstage biotechnology company committed to addressing one of the most critical challenges in oncology: treatment resistance and relapse, which continue to impact millions of cancer patients worldwide. The company has developed a first in class therapeutic approach targeting ALDH1, a key enzyme leveraged by cancer cells to detoxify harmful metabolic by-products and evade the effects of standard treatments. Unlike therapies focused on specific genetic mutations, Advanced BioDesign’s ALDH1 inhibitors act on a universal resistance mechanism shared across multiple tumor types. Its lead candidate, ABD3001, selectively disrupts cancer cell metabolism by inhibiting ALDH1, triggering apoptosis while sparing healthy cells—an innovative strategy designed to overcome chemoresistance. ABD3001 represents a major breakthrough in oncology, offering a novel, scalable, and mechanism-driven solution to treatment resistance. Supported by strategic partnerships, a pathway enabling rapid market entry, and a strong foundation in cellular biology, Advanced BioDesign is poised to redefine the standards of cancer therapy while delivering meaningful clinical and economic impact.

For more information: <https://www.a-biodesign.com> ; LinkedIn [@Advanced BioDesign](#)

Contacts :

Advanced BioDesign

Ismail CEYLAN – Chairman & CEO

+33 (0)777 686 687 / ismail.ceylan@a-biodesign.com